Literature DB >> 2974226

Lymphocyte subpopulations in malignant ascites of serous papillary ovarian adenocarcinoma. An immunocytochemical study.

J Guzman1, M Hilgarth, K J Bross, U Wiehle, A Ross, V Kresin, U Costabel.   

Abstract

The aim of this study was to investigate lymphocyte subpopulations in 17 patients with malignant ascites due to serous papillary adenocarcinoma of the ovary. Eight patients had not been treated prior to the study whereas nine patients had been treated by surgery and chemotherapy. A panel of monoclonal antibodies against surface markers that correlate with the immune functions of the lymphocytes was used. The lymphocyte subpopulations were identified by the immunoperoxidase adhesive slide assay, and the results in treated and untreated patients were compared. Both groups of patients showed lymphocytosis (41 +/- 25% and 33 +/- 14% of the total cells, respectively). The untreated patients had a significantly higher proportion of B cells (14 +/- 4% of lymphocytes) than did treated patients (7 +/- 2%). No differences were found between both groups regarding the helper-inducer/suppressor-cytotoxic T lymphocyte ratio. The proportion of lymphocytes expressing interleukin-2-receptors was higher in treated patients (6 +/- 2%) than in untreated patients (1.2 +/- 1%). Both groups showed a high percentage of natural killer/cytotoxic cells (17 +/- 7% and 18 +/- 5%, respectively). In the only chylous effusion in this study, there was an increase in helper-inducer and activated T lymphocytes. Future studies are required to document whether surface marker analysis of lymphocytes in malignant effusions may be useful for assessment of the prognosis and the results of treatment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2974226

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  3 in total

1.  Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC.

Authors:  G Mantovani; A Macciò; R Versace; M Pisano; P Lai; S Esu; M Ghiani; D Dessì; E Turnu; M C Santona
Journal:  J Mol Med (Berl)       Date:  1995-08       Impact factor: 4.599

Review 2.  Metastatic Carcinoma in Effusions.

Authors:  Vinod B Shidham
Journal:  Cytojournal       Date:  2022-01-31       Impact factor: 2.345

3.  Ascitic complement system in ovarian cancer.

Authors:  L Bjørge; J Hakulinen; O K Vintermyr; H Jarva; T S Jensen; O E Iversen; S Meri
Journal:  Br J Cancer       Date:  2005-03-14       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.